FDA head Janet Woodcock raises patent-related concerns to PTO director

Zachary Brennan

Senior Editor

While matters of drug pricing may not fall squarely under the FDA’s purview, acting FDA commissioner Janet Woodcock made clear the agency’s concerns around patents …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA head Janet Woodcock raises patent-related concerns to PTO director

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA head Janet Wood­cock rais­es patent-re­lat­ed con­cerns to PTO di­rec­tor

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

FDA head Janet Woodcock raises patent-related concerns to PTO director